4-(acetoxymethyl)-3-nitrobenzoic acid | 96965-30-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(acetoxymethyl)-3-nitrobenzoic acid
• 英文别名: 4-(Acetyloxymethyl)-3-nitrobenzoic acid
• CAS: 96965-30-9
• 化学式: C₁₀H₉NO₆
• 分子量: 239.185
• InChiKey: YQZFPOLVJNLVLN-UHFFFAOYSA-N

物化性质

• 沸点：
  387.7±37.0 °C(Predicted)
• 密度：
  1.435±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(acetoxymethyl)-3-nitrobenzoic acid 在 硫酸 、 一水合肼 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 氯仿 为溶剂， 反应 50.0h， 生成 Dts-Phe-ONb-tBu
  参考文献：
  名称：

  Three-dimensional orthogonal protection scheme for solid-phase peptide synthesis under mild conditions

  摘要：

  DOI：

  10.1021/ja00303a019
• 作为产物：
  描述：

  对溴甲基苯甲酸 在 硝酸 作用下， 以 溶剂黄146 为溶剂， 反应 17.0h， 生成 4-(acetoxymethyl)-3-nitrobenzoic acid
  参考文献：
  名称：

  Three-dimensional orthogonal protection scheme for solid-phase peptide synthesis under mild conditions

  摘要：

  DOI：

  10.1021/ja00303a019

文献信息

• Model Studies for New <i>o</i>-Nitrobenzyl Photolabile Linkers:  Substituent Effects on the Rates of Photochemical Cleavage
  作者：Christopher P. Holmes

  DOI：10.1021/jo961602x

  日期：1997.4.1

  the kinetics of their photolytic cleavage examined in solution. The linkers were prepared by amidation of the carboxylic acid anchoring tether with benzylamine, and the cleavable benzylic substituent was chosen to be either acetic acid or acetamide. Irradiation of the linkers in four solvents (methanol, p-dioxane, and aqueous buffer +/- dithiothreitol) at 365 nm and analysis via HPLC afforded kinetic

  制备了来自文献的模型苯甲酰基和邻硝基苄基光不稳定连接基，以及四个新的邻硝基苄基连接基，并在溶液中检查了其光解裂解的动力学。通过将羧酸锚定系链与苄胺酰胺化来制备接头，并且将可裂解的苄基取代基选择为乙酸或乙酰胺。接头在365 nm的四种溶剂（甲醇，对二恶烷和水性缓冲液+/-二硫苏糖醇）中进行辐照，并通过HPLC分析提供了适合比较目的的裂解动力学速率。发现苯甲酰基接头在水性条件下缓慢裂解，在有机溶剂中未观察到可裂解。已知的邻硝基苄基接头4在水性和有机溶剂中显示出适度的裂解速率。在苯环中引入两个烷氧基以生成基于藜芦基的连接基13a显着提高了裂解速率，另外引入苄基甲基（13b）使裂解速率增加了5倍。将锚固羧酸系链的长度从乙酸增加为丁酸（19），可以适度改善有机介质中的裂解动力学，并略微降低了在水中的分解速率。酰胺模型接头21的断裂速度比相应的酯键19快3至7倍。制备了酰胺产生接头26，并简要地研究了
• Synthesis and in Vitro Cytotoxic Activity of Compounds with Pro-Apoptotic Potential
  作者：Gisell Apicela Soares、Renata Barbosa de Oliveira、Saulo Fernandes de Andrade、Ricardo José Alves、Carlos Leomar Zani、Elaine Maria De Souza-Fagundes

  DOI：10.3390/molecules15010012

  日期：——

  In our search for new anticancer therapies, some compounds synthesized in our lab were selected and their potential cytotoxic activity was evaluated in vitro against two cancer cells lines including a solid tumor (UACC-62, melanoma) and a human lymphoma (JURKAT). Compounds showing cytotoxic activity were subjected to an apoptosis assay. Two compounds showed promising results.

  在我们寻找新的抗癌疗法的过程中，我们选择了一些在我们实验室合成的化合物，并在体外评估了它们针对两种癌细胞系（包括实体瘤（UACC-62，黑色素瘤）和人类淋巴瘤（JURKAT））的潜在细胞毒活性。对表现出细胞毒活性的化合物进行细胞凋亡测定。两种化合物显示出有希望的结果。
• Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection
  作者：Kenneth L. Granberg、Zhong-Qing Yuan、Bo Lindmark、Karl Edman、Johan Kajanus、Anders Hogner、Marcus Malmgren、Gavin O’Mahony、Anneli Nordqvist、Jan Lindberg、Stefan Tångefjord、Michael Kossenjans、Christian Löfberg、Jonas Brånalt、Dongmei Liu、Nidhal Selmi、Grigorios Nikitidis、Peter Nordberg、Ahlke Hayen、Anna Aagaard、Eva Hansson、Majlis Hermansson、Ida Ivarsson、Rasmus Jansson-Löfmark、Ulla Karlsson、Ulrika Johansson、Lena William-Olsson、Judith Hartleib-Geschwindner、Krister Bamberg

  DOI：10.1021/acs.jmedchem.8b01523

  日期：2019.2.14

  The mechanism-based risk for hyperkalemia has limited the use of mineralocorticoid receptor antagonists (MRAs) like eplerenone in cardio-renal diseases. Here, we describe the structure and property-driven lead generation and optimization, which resulted in identification of MR modulators (S)-1 and (S)-33. Both compounds were partial MRAs but still demonstrated equally efficacious organ protection as eplerenone after 4 weeks of treatment in uni-nephrectomized rats on high-salt diet and aldosterone infusion. Importantly, and in sharp contrast to eplerenone, this was achieved without substantial changes to the urine Na+/K+ ratio after acute treatment in rat, which predicts a reduced risk for hyperkalemia. This work led to selection of (S)-1 (AZD9977) as the clinical candidate for treating MR-mediated cardio-renal diseases, including chronic kidney disease and heart failure. On the basis of our findings, we propose an empirical model for prediction of compounds with low risk of affecting the urinary Na+/K+ ratio in vivo.
• SULFONAMIDE DERIVATIVES AND THEIR USE
  申请人：PHARMACOPEIA, INC.

  公开号：EP0751765B1

  公开（公告）日：2003-05-07
• EP0751765A4
  申请人：——

  公开号：EP0751765A4

  公开（公告）日：1997-05-28